Paul Carter Urology Limited 11861282 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of specialist medical activities. Digita Accounts Production Advanced 6.30.9574.0 true true 11861282 2024-04-01 2025-03-31 11861282 2025-03-31 11861282 bus:Director1 1 2025-03-31 11861282 bus:OrdinaryShareClass1 2025-03-31 11861282 bus:OrdinaryShareClass2 2025-03-31 11861282 bus:OrdinaryShareClass3 2025-03-31 11861282 bus:OrdinaryShareClass4 2025-03-31 11861282 bus:OrdinaryShareClass5 2025-03-31 11861282 bus:OtherShareClass1 2025-03-31 11861282 bus:OtherShareClass2 2025-03-31 11861282 core:RetainedEarningsAccumulatedLosses 2025-03-31 11861282 core:ShareCapital 2025-03-31 11861282 core:FinancialAssetsDesignatedFairValueThroughProfitOrLoss core:CurrentFinancialInstruments 2025-03-31 11861282 core:CurrentFinancialInstruments 2025-03-31 11861282 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 11861282 core:FurnitureFittingsToolsEquipment 2025-03-31 11861282 core:MotorVehicles 2025-03-31 11861282 bus:SmallEntities 2024-04-01 2025-03-31 11861282 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 11861282 bus:FilletedAccounts 2024-04-01 2025-03-31 11861282 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 11861282 bus:RegisteredOffice 2024-04-01 2025-03-31 11861282 bus:Director1 2024-04-01 2025-03-31 11861282 bus:Director1 1 2024-04-01 2025-03-31 11861282 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 11861282 bus:OrdinaryShareClass2 2024-04-01 2025-03-31 11861282 bus:OrdinaryShareClass3 2024-04-01 2025-03-31 11861282 bus:OrdinaryShareClass4 2024-04-01 2025-03-31 11861282 bus:OrdinaryShareClass5 2024-04-01 2025-03-31 11861282 bus:OtherShareClass1 2024-04-01 2025-03-31 11861282 bus:OtherShareClass2 2024-04-01 2025-03-31 11861282 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 11861282 bus:Agent1 2024-04-01 2025-03-31 11861282 core:FurnitureFittings 2024-04-01 2025-03-31 11861282 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 11861282 core:MotorVehicles 2024-04-01 2025-03-31 11861282 countries:EnglandWales 2024-04-01 2025-03-31 11861282 2024-03-31 11861282 bus:Director1 1 2024-03-31 11861282 core:FurnitureFittingsToolsEquipment 2024-03-31 11861282 core:MotorVehicles 2024-03-31 11861282 2023-04-01 2024-03-31 11861282 2024-03-31 11861282 bus:Director1 1 2024-03-31 11861282 bus:OrdinaryShareClass1 2024-03-31 11861282 bus:OrdinaryShareClass2 2024-03-31 11861282 bus:OrdinaryShareClass3 2024-03-31 11861282 bus:OrdinaryShareClass4 2024-03-31 11861282 bus:OrdinaryShareClass5 2024-03-31 11861282 bus:OtherShareClass1 2024-03-31 11861282 bus:OtherShareClass2 2024-03-31 11861282 core:RetainedEarningsAccumulatedLosses 2024-03-31 11861282 core:ShareCapital 2024-03-31 11861282 core:CurrentFinancialInstruments 2024-03-31 11861282 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 11861282 core:FurnitureFittingsToolsEquipment 2024-03-31 11861282 core:MotorVehicles 2024-03-31 11861282 bus:Director1 1 2023-04-01 2024-03-31 11861282 bus:Director1 1 2023-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 11861282

Paul Carter Urology Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

 

Paul Carter Urology Limited

Contents

Company Information

1

Accountants' Report

2

Balance Sheet

3 to 4

Notes to the Unaudited Financial Statements

5 to 9

 

Paul Carter Urology Limited

Company Information

Director

Dr P G Carter

Registered office

Wellesley House
204 London Road
Waterlooville
Hampshire
PO7 7AN

Accountants

MMO Limited
Wellesley House
204 London Road
Waterlooville
Hampshire
PO7 7AN

 

Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Paul Carter Urology Limited
for the Year Ended 31 March 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Paul Carter Urology Limited for the year ended 31 March 2025 as set out on pages 3 to 9 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of Paul Carter Urology Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Paul Carter Urology Limited and state those matters that we have agreed to state to the Board of Directors of Paul Carter Urology Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Paul Carter Urology Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Paul Carter Urology Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Paul Carter Urology Limited. You consider that Paul Carter Urology Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Paul Carter Urology Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

MMO Limited
Wellesley House
204 London Road
Waterlooville
Hampshire
PO7 7AN

5 August 2025

 

Paul Carter Urology Limited

(Registration number: 11861282)
Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

41,045

51,305

Current assets

 

Debtors

6

66,054

99,671

Other financial assets

5

-

80,000

Cash at bank and in hand

 

188,245

46,363

 

254,299

226,034

Creditors: Amounts falling due within one year

7

(21,011)

(28,171)

Net current assets

 

233,288

197,863

Total assets less current liabilities

 

274,333

249,168

Provisions for liabilities

(10,261)

(12,826)

Net assets

 

264,072

236,342

Capital and reserves

 

Called up share capital

8

160

160

Retained earnings

263,912

236,182

Shareholders' funds

 

264,072

236,342

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 5 August 2025
 

 

Paul Carter Urology Limited

(Registration number: 11861282)
Balance Sheet as at 31 March 2025

.........................................
Dr P G Carter
Director

 

Paul Carter Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Wellesley House
204 London Road
Waterlooville
Hampshire
PO7 7AN
England

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

All figures are presented in British Sterling, which is the functional currency of the company, and are rounded to the nearest £1.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Paul Carter Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Furniture and fittings

20% reducing balance

Motor vehicles

20% reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Paul Carter Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2024 - 1).

4

Tangible assets

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 April 2024

1,909

78,392

80,301

At 31 March 2025

1,909

78,392

80,301

Depreciation

At 1 April 2024

775

28,221

28,996

Charge for the year

226

10,034

10,260

At 31 March 2025

1,001

38,255

39,256

Carrying amount

At 31 March 2025

908

40,137

41,045

At 31 March 2024

1,134

50,171

51,305

 

Paul Carter Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

5

Other financial assets (current and non-current)

Financial assets at fair value through profit and loss
£

Total
£

Current financial assets

Cost or valuation

At 1 April 2024

80,000

80,000

Disposals

(80,000)

(80,000)

At 31 March 2025

-

-

Impairment

Carrying amount

At 31 March 2025

-

-

6

Debtors

Current

2025
£

2024
£

Trade debtors

23,433

43,210

Prepayments

296

836

Other debtors

42,325

55,625

 

66,054

99,671

7

Creditors

Creditors: amounts falling due within one year

2025
£

2024
£

Due within one year

Taxation and social security

21,011

28,171

 

Paul Carter Urology Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

8

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

100

100

100

100

Ordinary A shares of £1 each

10

10

10

10

Ordinary B shares of £1 each

10

10

10

10

Ordinary C shares of £1 each

10

10

10

10

Ordinary D shares of £1 each

10

10

10

10

Ordinary E shares of £1 each

10

10

10

10

Ordinary F shares of £1 each

10

10

10

10

160

160

160

160

9

Related party transactions

Transactions with the director

2025

At 1 April 2024
£

Other payments made to company by director
£

At 31 March 2025
£

Dr P G Carter

The directors loan account balance is undated, unsecured, interest free and repayable on demand.

55,625

(13,299)

42,326

2024

At 1 April 2023
£

Other payments made to company by director
£

At 31 March 2024
£

Dr P G Carter

The directors loan account balance is undated, unsecured, interest free and repayable on demand.

6,452

49,173

55,625